Convalescent Plasma as a Possible Treatment for COVID-19

Patients who are ill with COVID-19 may benefit from receiving convalescent plasma infusions containing antibodies from donors who have recovered from the disease and are proven to no longer be infected. Given the current public health emergency due to COVID-19, the FDA has recently fast-tracked the use of convalescent plasma. The purpose for this study is to assess if convalescent plasma collected from donors previously infected with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, can provide clinical benefit to those acutely ill with the virus and to evaluate if such treatment is safe. There will be two arms in the interventional study, where subjects will either be treated with convalescent plasma or fresh frozen plasma in a randomized and blinded manner. As an additional comparison, the clinical course of subjects enrolled during the period of the study who do not receive an alternative treatment for COVID-19 will be assessed.

NCT Number	NCT04442191
Lead Sponsor	University of Illinois at Chicago
Conditions	COVID-19
Enrollment	50 participants
Start Date	2020-05-05
Primary Completion	2021-05-05 (estimated)
Study Completion	2021-05-05 (estimated)
Updated on ClinicalTrials.gov	2020-06-22